profit from every $100 of sales.
$0$100
Corcept Therapeutics
$72.94-1.04% today
+92.6% in 1 year
1-year low $32.151-year high $123.57
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $80.11 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Corcept Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $402 million in 2022 to $761 million in 2025, with $99.7 million of profit last year.
SalesProfit
Corcept Therapeutics vs. similar companies
Corcept Therapeutics grows in the middle of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Corcept Therapeutics | 80.1× · Very expensive | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Corcept Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 354 | 366 | 402 | 482 | 675 | 761 | |
| 348 | 361 | 396 | 476 | 664 | 748 | |
| 128 | 124 | 113 | 107 | 137 | 45 | |
| 129 | 126 | 116 | 110 | 138 | 47 | |
| 106 | 113 | 101 | 106 | 141 | 100 | |
| 0.85 | 0.89 | 0.87 | 0.94 | 1.23 | 0.82 | |
| 98.4% | 98.6% | 98.7% | 98.7% | 98.4% | 98.3% | |
| 36.2% | 34.0% | 28.0% | 22.2% | 20.3% | 5.9% | |
| 30.0% | 30.7% | 25.2% | 22.0% | 20.9% | 13.1% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 572 | 424 | 583 | 622 | 841 | 837 |
| Cash | 76 | 78 | 66 | 136 | 128 | 120 |
| Total debt | – | – | 1 | 0 | 7 | 6 |
| Total liabilities | 48 | 48 | 82 | 115 | 161 | 189 |
| 523 | 376 | 502 | 507 | 680 | 648 | |
| 124 | 126 | 116 | 112 | 113 | 120 | |
| 19.4% | 26.2% | 17.7% | 16.7% | 15.8% | 5.4% | |
| 20.3% | 29.9% | 20.2% | 20.9% | 20.8% | 15.4% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 152 | 168 | 120 | 127 | 198 | 142 | |
| 1 | 0 | 0 | 0 | 2 | 0 | |
| 151 | 167 | 120 | 127 | 196 | 142 | |
| Dividends paid | – | – | – | – | – | – |
| – | – | 0 | 145 | 0 | 0 | |
| 34 | 43 | 42 | 49 | 61 | 85 |
Valuation
- 80.1×
- 154.0×
- –
- 12.3×
- 10.5×
- 56.3×
- 168.5×
- 1.8%
- 1.2%
- 0.0%
Profitability
- 98.3%
- 5.9%
- 13.1%
- -0.9%
- 5.5%
- 14.2%
- 7.5%
- 5.9%
- -1.2%
- 33.9%
Growth
- +16.6%
- −0.7%
- −27.6%
- –
- +1.1%
Financial health
- -2.5×
- 0.01
- 1.2%
- –
- 2.92
- 2.77
- 0.94
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 48%of 946
Bottom 42%of 872
Bottom 12%of 563
Top 35%of 868
Top 45%of 986
What analysts expect
- Average price target
- $73.00
- Range
- $30.00 – $100.00
- 3 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 30, 2026 | -0.30 | -0.14 | −111.3% |
| Feb 24, 2026 | 0.20 | 0.33 | −39.4% |
| Nov 4, 2025 | 0.16 | 0.18 | −11.1% |
| Jul 31, 2025 | 0.29 | 0.23 | +26.1% |
| May 5, 2025 | 0.17 | 0.17 | +0.0% |
| Feb 26, 2025 | 0.26 | 0.37 | −29.7% |
| Oct 30, 2024 | 0.41 | 0.28 | +46.4% |
| Jul 29, 2024 | 0.32 | 0.23 | +39.1% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
53No pass
Benjamin Graham
47No pass
Philip Fisher
47No pass
Peter Lynch
44No pass
Joel Greenblatt
4No pass
Charlie Munger
52No pass
Terry Smith
54No pass
Questions about Corcept Therapeutics
Is Corcept Therapeutics a good stock to buy?
A solid business, priced as if everything goes right. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Corcept Therapeutics AI analysis
What does Corcept Therapeutics do?
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It is in Biotechnology, based in Redwood City, CA, United States, with 730 employees.
Does Corcept Therapeutics pay a dividend?
No. Corcept Therapeutics does not pay a dividend at the moment.
Is Corcept Therapeutics stock halal?
Yes. Corcept Therapeutics passes our halal screen: its business is permitted and its debt is under 0.1% of its market value, under the 30% limit. How we check
How has Corcept Therapeutics stock done over the past year?
Up 92.6% over the past twelve months, to $72.94. It traded between $32.15 and $123.57 and is 41.0% below its high.
Who are Corcept Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Corcept Therapeutics's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.